Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Cleared to Begin Second Phase I Trial of siRNA Cancer Drug

Premium

Tekmira Pharmaceuticals this week announced that it has received approval from the US Food and Drug Administration to go forward with a new phase I study of its siRNA-based cancer drug TKM-PLK1 in collaboration with the National Cancer Institute.

Tekmira moved the drug, which targets polo-like kinase 1, into phase I testing early this year (GSN 1/6/2011). The company said that the new study, which will be conducted in parallel with the ongoing trial, will provide an “early opportunity to validate the drug's mechanism of action.”

"Patients in this new study, who will have either primary liver cancer or liver metastases, will receive TKM-PLK1 delivered directly into the liver via hepatic artery infusion,” Tekmira Preisdent and CEO Mark Murray said in a statement. “The trial design will allow us to measure tumor delivery, polo-like kinase 1 messenger RNA knockdown, and RNA interference activity in tumor biopsies from all of the patients treated.”

Interim phase I data on TKM-PLK1 is expected before year end.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.